This clinical trial is focused on studying the effects of a medication called mirikizumab in patients with ulcerative colitis. Ulcerative colitis is a chronic condition that causes inflammation and sores in the lining of the large intestine, leading to symptoms like abdominal pain and diarrhea. The treatment being tested, mirikizumab, is a type of medication known as a monoclonal antibody. It works by targeting a specific part of the immune system to help reduce inflammation.

The purpose of this study is to determine if long-term treatment with mirikizumab can help manage symptoms in patients with moderately to severely active ulcerative colitis. Participants in this study will receive mirikizumab as a solution for injection. The study will monitor the participants over time to assess the medication’s effectiveness and safety. This includes observing how many participants achieve clinical remission, which means a significant reduction or disappearance of symptoms.

Throughout the study, researchers will also look at other factors, such as the percentage of participants who achieve endoscopic remission, which is a reduction in visible inflammation during a medical examination of the colon. Additionally, the study will track the number of hospitalizations and surgeries related to ulcerative colitis, as well as changes in quality of life scores. The study aims to provide valuable information on the long-term benefits and safety of mirikizumab for individuals living with ulcerative colitis.